Alexion Pharmaceuticals (NASDAQ:ALXN) : $94.33 million worth of transactions were on upticks in Alexion Pharmaceuticals (NASDAQ:ALXN), compared to $69.22 million on downticks. The ratio between the two was 1.36, whereas, the net money flow stood at a healthy $25.12 million on Wednesdays session. The consistent buying on upticks in the stock accounted for $21.05million worth of trades. The total money flow into the stock stood at $21.05 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.67%. The stock was trading at $114.17, with a drop of $0.77 over the previous days close. The stock recorded 1.04% for the week.
In an insider trading activity, The Securities and Exchange Commission has divulged that Moriarty John B, officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, had unloaded 918 shares at an average price of $135.72 in a transaction dated on June 13, 2016. The total value of the transaction was worth $124,591. Currently the company Insiders own 4.41% of Alexion Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.86% . Institutional Investors own 98.83% of Alexion Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -2.23%.
The company shares have dropped -37.49% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $208.88 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $137.39 and the 200 Day Moving Average price is recorded at $148.89. Alexion Pharmaceuticals (NASDAQ:ALXN): The stock opened at $115.80 on Wednesday but the bulls could not build on the opening and the stock topped out at $116.79 for the day. The stock traded down to $112.20 during the day, due to lack of any buying support eventually closed down at $114.17 with a loss of -0.67% for the day. The stock had closed at $114.94 on the previous day. The total traded volume was 2,718,666 shares.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.